A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Cited by (645)

Items 101–200 of 645

1. Protein restriction and cancer
   Jie Yin, Wenkai Ren, Xingguo Huang, Tiejun Li, Yulong Yin · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
2. Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma
   Zhun Liu, Shaobin Yu, Shuting Ye, Zhimin Shen, Lei Gao, Ziyang Han, Peipei Zhang, Fei Luo, Sui Chen, Mingqiang Kang · 2019 · Journal of Proteomics
3. Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma
   Xinbing Zhu, Zhengzheng Li, Tongtong Li, Fei Long, Yuesheng Lv, Lei Liu, Xuefeng Liu, Qimin Zhan · 2018 · Biomedicine & Pharmacotherapy
4. Triptolide Induces Glioma Cell Autophagy and Apoptosis via Upregulating the ROS/JNK and Downregulating the Akt/mTOR Signaling Pathways
   Xihong Liu, Peiyuan Zhao, Xiujuan Wang, Lei Wang, Yingjun Zhu, Wei Gao · 2019 · Frontiers in Oncology
5. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
   Peter Stephen Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth F. Blackley, Jason Callahan, Kate Moodie, Courtney T. van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein et al. · 2022 · Cancer Discovery
6. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
   Robert Jr. Roskoski · 2021 · Pharmacological Research
7. Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine
   Mia Yang Ang, Teck Yew Low, Pey Yee Lee, Wan Fahmi Wan Mohamad Nazarie, Victor Guryev, Rahman Jamal · 2019 · Clinica Chimica Acta
8. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation
   Qiong Huang, Shaowei Li, Xingbin Hu, Mengting Sun, Qijing Wu, Huiru Dai, Yujing Tan, Fei Sun, Chunlin Wang, Xiaoxiang Rong et al. · 2020 · Journal of Experimental & Clinical Cancer Research
9. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome
   Juan María Roldán‐Romero, María Santos, Javier Lanillos, Eduardo J. Caleiras, Geòrgia Anguera, Pablo Maroto, Jesús García-Donás, Guillermo de Velasco, Ángel M. Martínez‐Montes, Bruna Calsina et al. · 2020 · Modern Pathology
10. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway
    Lisi Zeng, Quanxing Liao, Zhaowei Zou, Yue‐Feng Wen, Jingshu Wang, Chang Liu, Qingjun He, Nuoqing Weng, Judeng Zeng, Hongsheng Tang et al. · 2018 · Cellular Physiology and Biochemistry
11. The therapeutic landscape of hepatocellular carcinoma
    Suchira Gallage, Maria Garcia Beccaria, Marta Szydlowska, Mohammad Rahbari, Raphael U. Mohr, Frank Tacke, Mathias F Heikenwälder · 2021 · Med
12. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets
    Sebastian Zięba, Artur Kowalik, Kamil Zalewski, Natalia Rusetska, Krzysztof Goryca, Agata Piaścik, Marcin Misiek, Elwira Bakuła‐Zalewska, Janusz Kopczyński, Kamil Kowalski et al. · 2018 · Gynecologic Oncology
13. Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer
    Ellen R. Langille, Khalid N. Al‐Zahrani, Zhibo Ma, Minggao Liang, Liis Uusküla-Reimand, Roderic Espín, Katie Teng, Ahmad Malik, Helga Bergholtz, Samah El Ghamrasni et al. · 2022 · Cancer Discovery
14. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
    Garrett W. Rhyasen, Yi Yao, Jingwen Zhang, Austin M. Dulak, Lillian Castriotta, Kelly Jacques, Wei Zhao, Farzin Gharahdaghi, Maureen Mertens Hattersley, Paul D. Lyne et al. · 2018 · PLoS ONE
15. Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
    Eduard Porta‐Pardo, Alfonso Valencia, Adam Godzik · 2020 · FEBS Letters
16. A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer
    Jorge Gómez Tejeda Zañudo, Maurizio Scaltriti, Réka Albert · 2017 · Cancer Convergence
17. Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
    Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing L. Liu et al. · 2021 · Journal of Cancer
18. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
    Ashleigh Parkin, Jennifer Man, Paul Timpson, Marina Pajic · 2019 · FEBS Journal
19. Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products
    Leo L. Shen, Jerry Pelletier · 2019 · Natural Product Reports
20. PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib
    Angelica Pagliazzi, Teresa Oranges, Giovanna Traficante, Chiara Trapani, Flavio Facchini, Alessandra Martin, Alessandro Semeraro, Anna Lara Perrone, Cesare Filippeschi, Sabrina Giglio · 2021 · Frontiers in Pediatrics
21. Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
    Shadiya Fawzul Ameer, Muna Yusuf Mohamed, Qubaa Ahmed Elzubair, Elham Abdullatif M. Sharif, Wisam Nabeel Ibrahim · 2024 · Frontiers in Oncology
22. Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation
    Véronique Nogueira, Krushna Chandra Patra, Nissim Hay · 2018 · eLife
23. A comprehensive overview of oncogenic pathways in human cancer
    Feng Li, Tan Wu, Yanjun Xu, Qun Dong, Jing Xiao, Yingqi Xu, Qian Li, Chunlong Zhang, Jianxia Gao, Liqiu Liu et al. · 2019 · Briefings in Bioinformatics
24. ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma
    Qianping Chen, Zheng Wang, Lin Zhu, Dan Yao, Chen Wang, Yimeng Song, Songling Hu, Hongxia Liu, Yang Bai, Yan Pan et al. · 2020 · Frontiers in Cell and Developmental Biology
25. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
    Lishan Fang, Dane Ford-Roshon, Max Russo, Casey O’Brien, Xiaozhe Xiong, Carino Gurjao, Maximilien Grandclaudon, Srivatsan Raghavan, Steven M. Corsello, Steven A. Carr et al. · 2022 · Nature Communications
26. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
    Kensuke Tateishi, Taishi Nakamura, Tareq Adnan Juratli, Erik Abraham Williams, Yuko Matsushita, Shigeta Miyake, Mayuko Nishi, Julie J. Miller, Shilpa S. Tummala, Alexandria L. Fink et al. · 2019 · Clinical Cancer Research
27. Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance
    Gaurav Mehta, Pooja Khanna, Michael L. Gatza · 2019 · Journal of Mammary Gland Biology and Neoplasia
28. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma
    Safiya Khurshid, Matías Montes, Daniel F. Comiskey, Brianne Shane, Eleftheria Matsa, Francesca Jung, Chelsea Brown, Hemant Kumar Bid, Ruoning Wang, Peter J. Houghton et al. · 2022 · npj Precision Oncology
29. AKT and the Hallmarks of Cancer
    Eleonora Sementino, Dalal Hassan, Alfonso Bellacosa, Joseph R. Testa · 2024 · Cancer Research
30. Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer
    Mohammad Askandar Iqbal, Shumaila Iqbal Siddiqui, Asad ur Rehman, Farid Ahmad Siddiqui, Prithvi Kumar Singh, Bhupender Kumar, Daman Saluja · 2021 · Molecular Oncology
31. Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome
    Thiago Vidotto, Camila Morais Melo, William Lautert-Dutra, Luiz Paulo Chaves, Rodolfo Borges dos Reis, Jeremy Andrew Squire · 2023 · Scientific Reports
32. MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway
    Yangyang Wang, Yao-Qi Zhou, Jia-Xuan Xie, Xiang Zhang, Shuchang Wang, Qing Li, Li-Peng Hu, Shu‐Heng Jiang, Shuang‐Qin Yi, Jia Xu et al. · 2023 · Cellular Oncology
33. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma
    Jorge A. Benítez, Darren Finlay, Anthony S. Castanza, Alison D. Parisian, Jianhui Ma, Ciro Longobardi, Alex Rosa Campos, Raghavendra Vadla, Alejandro Izurieta, Gianluca Scerra et al. · 2021 · Neuro-Oncology
34. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
    Sihong Chen, Yingxi Zhao, Shougeng Liu, Jiayu Zhang, Yehuda G. Assaraf, Wei Cui, Lihui Wang · 2022 · Drug Resistance Updates
35. Connecting Proteomics to Next‐Generation Sequencing: Proteogenomics and Its Current Applications in Biology
    Teck Yew Low, M. Aiman Mohtar, Mia Yang Ang, Rahman Jamal · 2018 · PROTEOMICS
36. eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer
    Tim Kong, Yibo Xue, Regina Cencic, Xianbing Zhu, Anie Monast, Zheng Fu, Virginie Pilon, Veena Sangwan, Marie‐Christine Guiot, William D. Foulkes et al. · 2019 · Molecular Cancer Therapeutics
37. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
    Andrés García-Sampedro, Gabriella Gaggia, Alexander Ney, Ismahan Mahamed, Pilar Acedo · 2021 · Journal of Clinical Medicine
38. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
    Benoît Thibault, Fernanda Ramos‐Delgado, Elvire Pons Tostivint, Nicole Therville, Célia Cintas, Silvia Arcucci, Stéphanie Cassant‐Sourdy, Gabriela Reyes‐Castellanos, Marie Tosolini, Amélie V. Villard et al. · 2021 · EMBO Molecular Medicine
39. Pan-Cancer Analysis Reveals Synergistic Effects of CDK4/6i and PARPi Combination Treatment in RB-Proficient and RB-Deficient Breast Cancer Cells
    Songyu Li, Yixiang Zhang, Na Wang, Rong Guo, Qiaoling Liu, Changsheng Lv, Jinguang Wang, Lina Wang, Qingkai Yang · 2018 · Cell Death and Disease
40. PI3K / AKT pathway promotes keloid fibroblasts proliferation by enhancing glycolysis under hypoxia
    Qifei Wang, Xin Chun Yang, Jianxun Ma, Xiang Xie, Yimou Sun, Xu Chang, Hongsen Bi, Hongyu Xue, Zelian Qin · 2022 · Wound Repair and Regeneration
41. Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
    Alexandre Bertucci, François Bertucci, Anthony Gonçalvès · 2023 · Cancers
42. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review
    Yuanze Wang, Micky Daniel Tortorella · 2021 · European Journal of Medicinal Chemistry
43. Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway
    Yuzhen Zhu, Yu Zhong, Xun Long, Zhu Zhu, Yu Zhou, Hua Ye, Xiaobin Zeng, Xuebao Zheng · 2019 · Pharmaceutical Biology
44. From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy
    Afshin Derakhshani, Zeinab Rostami, Hossein Safarpour, Mahdi Abdoli Shadbad, Niloufar Sadat Nourbakhsh, Antonella Argentiero, Sina Taefehshokr, Neda Jalili Tabrizi, Omid Kooshkaki, Reza Vaezi Astamal et al. · 2021 · Molecules
45. RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
    Wang, Chun, Chen, Zhihang, Yi, Yun, Ding, Yang, Xu, Fei, Kang, Hui, Lin, Kun, Shu, Xiawen, Zhong, Zibiao, Zhang, Zhonglin et al. · 2024 · Oncogene
46. The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
    Cun Liu, Kejia Wang, Jing Zhuang, Chundi Gao, Huayao Li, Lijuan Liu, Fubin Feng, Chao Zhou, Kang Yao, Laijun Deng et al. · 2019 · Frontiers in Pharmacology
47. Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies
    Laurence Haddadin, Xueqin Sherine Sun · 2025 · Cells
48. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19)
    Xiaoling Li, Qin Qiu, Mingyue Li, Haowen Lin, Shi‐Lin Cao, Qu Wang, Zishi Chen, Wenhao Jiang, Wen Zhang, Yuge Huang et al. · 2021 · Aging
49. SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance
    Arturo Orlacchio, Michela Ranieri, Martina Brave, Valeria G. Antico Arciuch, Toni S. Forde, Daniela De Martino, Karen E. Anderson, Phillip T. Hawkins, Antonio Di Cristofano · 2017 · Cancer Research
50. Mammalian Target of Rapamycin
    Matthew F. Wipperman, David C. Montrose, Antonio M. Gotto, David P. Hajjar · 2019 · American Journal Of Pathology
51. Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
    Brian D. Yard, Priyanka Gopal, Kristina Bannik, Gerhard Siemeister, Urs B. Hagemann, Mohamed E. Abazeed · 2019 · Cancer Research
52. Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma
    Demin Fan, Qiang Liu, Fei Wu, Na Liu, Hongyi Qu, Yijiao Yuan, Yong Li, Huayu Gao, Juntao Ge, Yue Xu et al. · 2020 · PeerJ
53. Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly
    Hengqing Cui, Gang Han, Bin Sun, Fang Xia, Xinyi Dai, Shengbo Zhou, Hailei Mao, Bin Wang · 2020 · Cell Death and Disease
54. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers
    Komal L. Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid M. Aljumaily et al. · 2020 · Clinical Cancer Research
55. Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers
    Diana Monsivais, Yasmin M. Vasquez, Fengju Chen, Yiqun Zhang, Darshan Shimoga Chandrashekar, John C. Faver, Ramya P. Masand, Michael E. Scheurer, Sooryanarayana Varambally, Martin Matthew Matzuk et al. · 2021 · Oncogene
56. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
    Chiara Tarantelli, Antonio Lupia, Anastasios Stathis, Francesco Bertoni · 2020 · International Journal of Molecular Sciences
57. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular
    Ou Li, Li Li, Yunru Sheng, Kun Ke, Jianzhang Wu, Yiping Mou, Mingyang Liu, Weiwei Jin · 2023 · Cancer Letters
58. G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I via PI3K/Akt Activation in Bladder Cancer
    X.F. Steven Zheng, Jiawei Chen, Minhua Deng, Kang Ning, Yulu Peng, Zhenhua Liu, Xiangdong Li, Zhaohui Zhou, Huancheng Tang, Yaoying Li et al. · 2023 · Advanced Science
59. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains
    Florian Weinberg, Ricarda Griffin, Martina Fröhlich, Christoph Heining, Sandra L. Braun, Corinna Spohr, Mary Iconomou, Viola Hollek, Michael Röring, Peter Horak et al. · 2019 · Oncogene
60. ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro
    Lei Song, Yi Luo, Shaoling Li, Ming Hong, Qi Wang, Xiaoling Chi, Cong Yang · 2020 · Drug Design Development and Therapy
61. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
    Robert Jr. Roskoski · 2021 · Pharmacological Research
62. lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway
    Qingkun Jiang, Zhonghao Wang, Qi Qi, Jialun Li, Yuqi Xin, Jiaxuan Qiu · 2021 · Molecular Therapy — Oncolytics
63. Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas
    Fengju Chen, Yiqun Zhang, Sooryanarayana Varambally, Chad J. Creighton · 2018 · Molecular Cancer Research
64. Pinocembrin Inhibits the Proliferation and Metastasis of Breast Cancer via Suppression of the PI3K/AKT Signaling Pathway
    Xinbing Zhu, Rongnian Li, Chen Wang, Shuo Zhou, Yujia Fan, Shuang Ma, Didi Gao, Nian Gai, Jing Yang · 2021 · Frontiers in Oncology
65. AKT mutant allele-specific activation dictates pharmacologic sensitivities
    Tripti Shrestha-Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T.A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao et al. · 2022 · Nature Communications
66. The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors
    Samaneh Mostafavi, Hamidreza Zalpoor, Zuhair Mohammad Hassan · 2022 · Cellular & Molecular Biology Letters
67. Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
    Jorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, Kailey J. Kowalski, Gabriela N. Johnson, Guotai Xu, Jose M Baselga, Maurizio Scaltriti, Anthony G. Letai, Joan Montero et al. · 2021 · Cancer Research
68. Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?
    Christopher K. McCann, Emma M. Kerr · 2021 · Cancers
69. Gene Expression Profiles in Cancers and Their Therapeutic Implications
    Chad J. Creighton · 2023 · The Cancer Journal
70. Personalization of prostate cancer therapy through phosphoproteomics
    Wei Yang, Michael R. Freeman, Natasha Kyprianou · 2018 · Nature Reviews Urology
71. PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling
    Hongmin Gao, Juan Zhang, Xiaohong Ren · 2019 · Bioscience Reports
72. Chaetocochin J, an epipolythiodioxopiperazine alkaloid, induces apoptosis and autophagy in colorectal cancer via AMPK and PI3K/AKT/mTOR pathways
    Song Hu, Jie Yin, Shan Yan, Ping Hu, Jianzheng Huang, Geng Zhang, Fuqian Wang, Qingyi Tong, Yonghui Zhang · 2021 · Bioorganic Chemistry
73. Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
    Christen A. Khella, Gaurav A. Mehta, Rushabh N. Mehta, Michael L. Gatza · 2021 · Journal of Personalized Medicine
74. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
    Athina Ganner, Christina Gehrke, Marinella Klein, Lena Thegtmeier, Tanja Matulenski, Laura Wingendorf, Lu Wang, Felicitas Pilz, Lars Greidl, Lisa Meid et al. · 2021 · Scientific Reports
75. Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer
    Zhiqiang Peng, Fang Wei, Bo Wu, Ming Sheng He, Shaohua Li, Jun Wei, Yang Hao, Lujia Jin, Mingqiu Liu, Xin Zhang et al. · 2024 · Nature Chemical Biology
76. Molecular patterns in salivary duct carcinoma identify prognostic subgroups
    Simon Andreas Mueller, Marie-Emilie A. Gauthier, James Blackburn, John P. Grady, Spiridoula Kraitsek, Elektra Hajdu, Matthias S. Dettmer, Jane Esther Dahlstrom, Cheok Soon Lee, Peter P. Luk et al. · 2020 · Modern Pathology
77. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway
    Han Chen, Hengxiao Wang, Xiqiao Yu, Shuping Zhou, Yueying Zhang, Zhaopeng Wang, Shuhong Huang, ZHAOXIA WANG · 2020 · BMC Cancer
78. Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors
    Svenja Wiechmann, Benjamin Ruprecht, Theresa Siekmann, Runsheng Zheng, Martin Frejno, Elena Kunold, Thomas Bajaj, Daniel Paul Zolg, Stephan A. Sieber, Nils C. Gassen et al. · 2021 · ACS Chemical Biology
79. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial
    Raphael J. Morscher, Caroline Brard, Pablo Berlanga, Lynley V. Marshall, Nicolás André, Jonathan Rubino, Isabelle Aerts, Émilie De Carli, Nadège Corradini, Souad Nebchi et al. · 2021 · European Journal of Cancer
80. Making Use of Cancer Genomic Databases
    Chad J. Creighton · 2018 · Current Protocols in Molecular Biology
81. mTOR and Tumor Cachexia
    A. P. Duval, C. Jeanneret, Tania Santoro, O. Dormond · 2018 · International Journal of Molecular Sciences
82. Dietary Carotenoids in Head and Neck Cancer—Molecular and Clinical Implications
    Katarzyna Starska · 2022 · Nutrients
83. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer
    Peiwen Yang, Panling Xu, Chien‐shan Cheng, Juying Jiao, Yuan Wu, Shu Dong, Jing Xie, Xiaoyan Zhu · 2022 · Journal of Ethnopharmacology
84. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
    Murat Ihlamur, Buşra Akgül, Yağmur Zengin, Şenay Vural Korkut, Kübra Kelleci, Emrah Şefik Abamor · 2023 · Current Molecular Medicine
85. The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma
    Q. Jiang, Jing Xiao, Yao-Ching Hsieh, Neha Kumar, L. Han, Y. Zou, Huang Li · 2024 · Biomedicines
86. Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway
    Meisam Jafarzadeh, Bahram Mohammad Soltani, Masoud Soleimani, Saman Hosseinkhani · 2020 · Biochimie
87. Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer
    Jennifer Marx Fernandes, Elisa Helena Farias Jandrey, Fernanda Christtanini Koyama, Kátia Ramos Moreira Leite, Anamaria A. Camargo, Erico Tosoni Costa, Rodrigo Oliva Perez, Paula Fontes Asprino · 2020 · Diseases of the Colon & Rectum
88. Discovery of putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in acute myeloid leukemia cells
    W. Frank Lenoir, Micaela C. Morgado, Peter C. DeWeirdt, Megan E. McLaughlin, Audrey L Griffith, Annabel K. Sangree, Marissa N. Feeley, Nazanin Esmaeili Anvar, Eiru Kim, Lori L. Bertolet et al. · 2021 · Nature Communications
89. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
    Karina A. Miller, Seamus E. Degan, Yanqing Wang, Joseph Cohen, Sheng‐Yu Ku, David W. Goodrich, Irwin H. Gelman · 2023 · Oncogene
90. The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
    Bisheng Cheng, Lingfeng Li, Yongxin Wu, Tianlong Luo, Chen Tang, Qiong Wang, Qianghua Zhou, Jilin Wu, Yiming Lai, Dingjun Zhu et al. · 2023 · Cell & Bioscience
91. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models
    Stefano Rossetti, Aaron Broege, Adrish Sen, Salmaan Ahmed Khan, Ian A. MacNeil, Jhomary S. Molden, Ross A. Kopher, Stephen Schulz, Lance G. Laing · 2024 · npj Breast Cancer
92. The influence of patient sex on clinical approaches to malignant glioma
    Silvia Matteoni, Claudia Abbruzzese, Veronica Villani, Walter Malorni, Andrea Pace, Paola Matarrese, Marco Giorgio Paggi · 2019 · Cancer Letters
93. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics
    Muireann Ní Bhaoighill, Elaine A. Dunlop · 2019 · Cancer Drug Resistance
94. The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer
    Xijuan Liu, Giada Zurlo, Qing Hua Zhang · 2020 · Advances in experimental medicine and biology
95. Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
    Ralitsa Radostinova Madsen, Emily C. Erickson, Oscar M. Rueda, Xavier Robin, Carlos Caldas, Alex Toker, Robert K. Semple, Bart Vanhaesebroeck · 2021 · PLoS Genetics
96. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease
    Dawid Mehlich, Anna A. Marusiak · 2022 · Cancer Letters
97. Growth or death? Control of cell destiny by mTOR and autophagy pathways
    Mahmoud I. M. Khalil, Mohamad Moustafa Ali, Jasmine Holail, Marwa Houssein · 2023 · Progress in Biophysics and Molecular Biology
98. Tuberous sclerosis complex–associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt
    Zordan, Paola, Cominelli, Manuela, Cascino, Federica, Tratta, Elisa, Poliani, Pietro L., Galli, Rossella · 2018 · Journal of Clinical Investigation
99. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells
    Francesca Chiarini, Camilla Evangelisti, Giovanna Lattanzi, James Andrew McCubrey, Alberto Maria Martelli · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
100. LIM and SH3 protein 1 induces glioma growth and invasion through PI3K/AKT signaling and epithelial-mesenchymal transition
     Chuanhong Zhong, Xianglong Li, Bei Tao, Lilei Peng, Tangming Peng, Xiaobo Yang, Xiangguo Xia, Ligang Chen · 2019 · Biomedicine & Pharmacotherapy